PAYNE JOHN BERNARD 4

What Happened

• John B. Payne, President, CEO and Director of Zivo Bioscience, reported a purchase of 11,709 shares on 2026-01-26 at $8.54 per share, for a total reported cost of $99,995. The Form 4 classifies the transaction as a purchase (code P), reported as an open‑market or private purchase.

Key Details

• Transaction date: 2026-01-26; reported on Form 4 filed 2026-01-28 (appears timely).
• Price per share: $8.54; shares acquired: 11,709; total value: $99,995.
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Notable footnotes/plans: No 10b5‑1 plan, tax‑withholding, or other special footnotes disclosed in the excerpt.
• Transaction type: Direct purchase (not an option exercise, award, gift, or sale).

Context

• This was a straight purchase by the company’s CEO. Insider purchases are often watched by investors as one input (along with other data) about management’s view of the company, but they do not by themselves prove future performance.